Learning to Use a Biomarker More About B-Type Natriuretic Peptide⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Mills, Roger M.
L
M
R
M
L
p
p
a
p
o
r
e
s
s
u
a
o
s
w
S
a
v
s
h
B
S
r
v
s
p
a
s
w
b
m
a
b
e
n
p
p
d
n
a
b
f
s
m
o
p
s
f
a
p
s
B
A
h
i
F
s
l
a
m
0
1
t
f
s
d
y
v
7
h
p
r
q
w
1
n
t
p
*
v
A
S
Journal of the American College of Cardiology Vol. 51, No. 24, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2008.02.067EDITORIAL COMMENT
earning to Use a Biomarker
ore About B-Type Natriuretic Peptide*
oger M. Mills, MD, FACC
ountain View, California
“Human beings, who are almost unique in having the ability to
learn from the experience of others, are also remarkable for their
apparent disinclination to do so.”
Douglas Adams, Last Chance to See (1)
earning to interpret immunoreactive B-type natriuretic
eptide (iBNP) levels in heart failure can be compared to
utting together a jigsaw puzzle. The report from Nishii et
l. (2) in this issue of the Journal gives us an important new
iece. The authors report a single-center observational study
f 83 Japanese patients with dilated cardiomyopathy who
emained clinically stable for at least 6 months after an
pisode of decompensated heart failure. They followed the
ubjects for another 18 months or until death or readmis-
ion. In this highly selected population, the B-type natri-
See page 2329
retic peptide (BNP) level at 6 months post-discharge was
strong predictor of subsequent outcomes, with a cut-point
f 190 pg/ml separating those with improved left ventricular
ystolic function and a low rate of readmission from those
ho were subsequently rehospitalized for heart failure.
ince the biomarker puzzle is coming together so rapidly,
nd with so many investigators contributing, a brief over-
iew of our current understanding of BNP and the data
upporting its importance as a cardiac biomarker should
elp to place these new findings in context.
rief Review of BNP
hort-term regulation of total body salt and water balance
equires the coordinated interaction of brain, heart, blood
essels, and kidneys to set dietary intake and renal excretion of
alt and water within parameters that maintain cardiac filling
ressures and organ perfusion. The renin-angiotensin-
ldosterone-sympathetic axis and the natriuretic peptide
ystem serve to respectively promote or inhibit salt and
ater retention. For animals in an aqueous environment,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.f
From Scios Inc., Mountain View, California. The author is a full-time employee of
cios Inc.oth systems are important. In contrast, in land-dwelling
ammals, the renin-angiotensin-aldosterone-sympathetic
xis system is strikingly physiologically dominant. Although
y 1981, the work of DeBold et al. (3) clearly pointed to the
xistence of natriuretic hormones, the structure of BNP was
ot defined until 1988 (4); our understanding of natriuretic
eptides has progressed dramatically since.
Under normal conditions, myocyte stretch constitutes the
rimary stimulus for natriuretic peptide release (5). Recent
ata suggest that the mechanisms for processing the large
atriuretic peptide prohormone, proBNP, to the small
ctive 32-amino-acid molecule BNP may be overwhelmed
y the sustained pressure-volume overload of chronic heart
ailure. Both Western blot (6) and sophisticated mass
pectroscopy studies (7) (Ute Schellenberger, personal com-
unication, September 2007) confirm that proBNP and
ther related large molecules, which have little or no
hysiologic activity, make up a large amount of the sub-
tances measured by commercially available immunoassays
or BNP in clinical heart failure patients. Nonetheless,
mple clinical data confirm that measurement of iBNP
rovides an extraordinarily useful biomarker of cardiac
tress.
iomarker Data in Heart Failure
s individuals progress from asymptomatic good health to
ighly symptomatic heart failure, the threshold level for
BNP levels associated with increased risk rises. In the
ramingham Offspring study, Wang et al. (8) studied 3,346
ubjects without heart failure. B-type natriuretic peptide
evels above the 80th percentile values of 20.0 pg/ml for men
nd 23.3 pg/ml for women “were associated with
ultivariable-adjusted hazard ratios of 1.62 for death (p 
.02), 1.76 for a first major cardiovascular event (p  0.03),
.91 for atrial fibrillation (p  0.02), 1.99 for stroke or
ransient ischemic attack (p  0.02), and 3.07 for heart
ailure (p  0.002)” (8).
In the BNP (Breathing Not Properly) multinational
tudy, Maisel et al. (9) studied 1,586 adult patients with
yspnea. Using a receiver-operator characteristic curve anal-
sis, they reported, “A B-type natriuretic peptide cutoff
alue of 100 pg/ml had a sensitivity of 90%, a specificity of
6%, and an accuracy of 83% for differentiating congestive
eart failure from other causes of dyspnea” (9).
Fonarow et al. (10) and the ADHERE (Acute Decom-
ensated Heart Failure National Registry) investigators
etrospectively analyzed admission BNP levels and subse-
uent mortality in 48,629 patients. “Quartiles (Q) of BNP
ere Q1 (430 pg/ml), Q2 (430 to 839 pg/ml), Q3 (840 to
,729 pg/ml), and Q4 (1,730 pg/ml).” “There was a
ear-linear relationship between BNP and in-hospital mor-
ality: Q1 (1.9%), Q2 (2.8%), Q3 (3.8%), and Q4 (6.0%),
 0.0001” (10).
After inpatient therapy for an episode of acute heartailure, iBNP cutoff values for increased risk fall again.
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June 17, 2008:2336–8 Editorial Commentogeart et al. (11) studied 223 subjects in a derivation/
alidation study. The pre-discharge iBNP level was the best
redictor of subsequent death or readmission. “Using the
redischarge BNP level (as a continuous variable and after
djustment for covariables), similar results were obtained
or: 1) death or re-admission at 1 month (hazard ratio 1.17
1.06 to 1.28], p  0.002); and 2) re-admission at 6 months
hazard ratio 1.25 [1.16 to 1.34], p  0.001) . . . a BNP
evel of 350 ng/l was found to have the best compromise
etween sensitivity and specificity for predicting death or
e-admission at 6 months” (11).
The STARS (Plasma Brain Natriuretic Peptide Guided
herapy to Improve Outcome in Heart Failure) investi-
ators (12) enrolled 220 subjects at least 1 month after
ospitalization with symptomatic heart failure in a trial of
NP-guided versus clinical management. They found “In
he BNP group, mean plasma BNP levels significantly
ecreased during follow-up from 352  260 pg/ml at
aseline to 284  180 pg/ml at 3-month follow-up (p 
.03)” (12). This was “associated with a lower risk of
eath related to heart failure or hospital stay related to
eart failure than the usual strategy based on clinical
xpertise” (12).
Now, Nishii et al. (2 ) have added yet another piece of
ata, from stable nonischemic patients at 6 months after
ischarge, showing 190 pg/ml as a risk cutoff. These
ubjects represent an extremely low-risk group. They had
elatively low iBNP levels at discharge from hospital and
ere stable for 6 months in New York Heart Association
unctional class I to II on oral therapy. Even in this
Figure 1 Biomarker Data in HF
Cutpoints for immunoreactive B-type natriuretic peptide (iBNP) levels associated w
then to admission, discharge, 1 month post-discharge, and 6 months post-dischar
acute decompensated heart failure; HF  heart failure; NYHA  New York Heart Aow-risk group, relatively higher versus relatively lowerBNP levels effectively differentiated patients at increased
ubsequent risk.
The broad outlines of a picture have emerged, as shown
n Figure 1. “Cutoff values” for a high-risk BNP level in the
eneral population, in those at risk for heart failure, or
ecognized heart failure patients vary across a wide spectrum
f values depending on clinical context. Skeptics will decry
his as too confusing. Proponents will point out the mar-
elous range of utility that iBNP offers, including long-term
isk assessment, emergency diagnosis, short-term and
onger-term prognosis, and objectively guided therapy. Us-
ng iBNP data as a tool, however, requires making the effort
o understand it.
For clinician-investigators, the more important question
emains unanswered. Now that we can identify patients at
ncreased risk across a wide spectrum of cardiovascular
isease, can we intervene with drugs, devices, or improved
are strategies, or all of these, to effectively change the
ismal natural history of the heart failure syndrome? With a
etter understanding of iBNP, we have a new tool in hand
o plan better heart failure treatment trials; the challenge
ow is to skillfully execute them.
eprint requests and correspondence: Dr. Roger M. Mills,
edical Affairs, Scios Inc., 1900 Charleston Road, Mountain
iew, California 94043. E-mail: rmills@scius.jnj.com.
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